EXOPOLYSACCHARIDE OF SHIGELLA SONNEI BACTERIA METHOD FOR PRODUCING SAME VACCINE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

摘要

For the first time, O-specific polysaccharide antigens, the Siegelosone, phase I, and extracellular polysaccharides, were produced, which resulted in the formation of the O-linked polysaccharide by the (1 → 3) Amino-2- (N-acetyl) amino-2,4-dideoxy- beta -D-galactopyranosyl] - (1 → 4) -O- [2- -Deoxy- [alpha] -L-altripiranylic acid], which is a natural natural compound in the form of bacterial capsular polysaccharides consisting of from 1 to 100 repeating disaccharide units. Extracellular polysaccharide has a molecular weight of from 0.4 to 400 kDa, non-toxic lipid component, that is, non-contains hydroxylated fatty acids, exhibits a low heat generating properties and high immunogenicity, S in a mammal including a human by induction of synthesis of specific antibodies against bovine nose, and generates a mucosal protection against Shigella small Nei Siegel rajeung. Without using lipid polysaccharides as a production source, extracellular polysaccharides with a high degree of purity are produced in high yield from liquid phase cultures of S. sonnei bacteria by workable industrial methods. Effective, highly specific and safe vaccines for the prevention and / or treatment of schizophrenia schizophrenia, as well as pharmaceutical compositions with a broad spectrum of action to control the immune response, as well as broad action spectrum, are based on the above-described extracellular polysaccharides .